Uses of morelloflavone

Abstract

Provided herein are methods of treating postangiplasty, in-stent restenosis or atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone with or with a effective dose of one or more of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. Also provided are pharmaceutical compositions comprising a morelloflavone or pharmaceutical combinations comprising a morelloflavone and one of an HMG-CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent.

1 . A method for treating postangiplasty or in-stent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone. 
     
     
         2 . The method of  claim 1 , wherein said morelloflavone retards the progression of atherosclerosis. 
     
     
         3 . The method of  claim 1 , wherein said morelloflavone retards migration of vascular smooth muscle cells. 
     
     
         4 . The method of  claim 1 , wherein said morelloflavone decreases activation of ERK, RhoA, Rac, FAK and cSrc. 
     
     
         5 . The method of  claim 1 , wherein said individual is at risk for percutaneous coronary intervention. 
     
     
         6 . The method of  claim 1 , wherein said individual has atherosclerosis in coronary arteries, cerebral arteries, renal arteries, aorta, or peripheral arteries. 
     
     
         7 . The method of  claim 1 , wherein said morelloflavone is administered orally. 
     
     
         8 . The method of  claim 1 , wherein said morelloflavone is administered is a dose of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight. 
     
     
         9 . The method of  claim 1 , further comprising the step of administering an HMG-CoA reductase inhibitor. 
     
     
         10 . The method of  claim 8 , wherein said statin is selected from the group consisting of Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, Simvastatin. 
     
     
         11 . A method for treating postangiplasty or in-stent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone in a dose of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight. 
     
     
         12 . A method for treating postangiplasty or in-stent restenosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone and an HMG-CoA reductase inhibitor. 
     
     
         13 . The method of  claim 12 , further comprising administering an HMG CoA reductase inhibitor or a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent. 
     
     
         14 . The method of  claim 13 , wherein said hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent is selected from the group consisting of 1,2,3 or more MTP inhibitors, squalene synthetase inhibitors, fibric acid derivatives, PPAR .alpha. agonists, PPAR dual .alpha./.gamma. agonists, PPAR .delta. agonists, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na.sup.+/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, cholesteryl ester transfer protein inhibitors, bile acid sequestrants, or nicotinic acid and derivatives thereof, ATP citrate lyase inhibitors, phytoestrogen compounds, an HDL upregulators, LDL catabolism promoters, antioxidants, PLA-2 inhibitors, antihomocysteine agents, HMG-CoA synthase inhibitors, lanosterol demethylase inhibitors, or sterol regulating element binding protein-I agents. 
     
     
         15 . The method of  claim 12 , further comprising administering a platelet aggregation inhibitor. 
     
     
         16 . The method of  claim 15 , wherein said platelet aggregation inhibitor is selected from the group consisting of aspirin, clopidogrel, ticlopidine, dipyridamole, ifetroban, abciximab, tirofiban, eptifibatide, anagrelide, CS-737, melagatran, ximelagatran, razaxaban. 
     
     
         17 . A pharmaceutical composition comprising a morelloflavone and a pharmaceutically acceptable carrier therefor. 
     
     
         18 . A pharmaceutical combination comprising a morelloflavone and one of:
 a HMG CoA reductase inhibitor compound;   a hypolipidemic agent or lipid-lowering agent or other lipid agent or lipid modulating agent or anti-atherosclerotic agent; or   a platelet aggregation inhibitor.   
     
     
         19 . A method for treating atherosclerosis in an individual in need of such treatment, comprising the step of administering to said individual an effective dose of morelloflavone. 
     
     
         20 . The method of  claim 19 , wherein said morelloflavone retards migration of vascular smooth muscle cells. 
     
     
         21 . The method of  claim 19 , wherein said individual has atherosclerosis in coronary arteries, cerebral arteries, renal arteries, aorta, or peripheral arteries. 
     
     
         22 . The method of  claim 19 , wherein said morelloflavone is administered orally. 
     
     
         23 . The method of  claim 19 , wherein said morelloflavone is administered is a dose of from about 0.1 mg/kg to about 100 mg/kg of the individual's body weight. 
     
     
         24 . The method of  claim 19 , further comprising the step of administering an HMG-CoA reductase inhibitor. 
     
     
         25 . The method of  claim 24 , wherein said statin is selected from the group consisting of Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin, Simvastatin.